4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Hangzhou Diagens Biotechnology Co., Ltd. (2526) operates in the Medical Devices industry and is headquartered in Hangzhou, China with about 166 employees. Its market capitalization is roughly CNY 37 billion. In the fiscal year ended 2025-12-31, 2526 reported CNY 164M in revenue and (CNY 67M) in net income.
Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | CNY 164M | CNY 70M | CNY 53M |
| Gross Profit | CNY 118M | CNY 46M | CNY 38M |
| Operating Income (EBIT) | (CNY 60M) | (CNY 22M) | (CNY 41M) |
| Net Income | (CNY 67M) | (CNY 43M) | (CNY 56M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | CNY 53M | CNY 51M |
| Gross Profit | CNY 33M | CNY 38M |
| Operating Income (EBIT) | (CNY 27M) | CNY 14M |
| Net Income | (CNY 30M) | CNY 7M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | CNY 216M | CNY 212M | CNY 221M |
| Total Liabilities | CNY 50M | CNY 38M | CNY 307M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2526 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms